2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase.

British Journal of Pharmacology
Wei-Ling ChangJih-Hwa Guh

Abstract

The c-Jun N-terminal kinase (JNK) and tubulin are, frequently, targets for developing anti-cancer drugs. A major obstacle to successful development is P-glycoprotein (P-gp)-mediated resistance. Here, we have assessed a compound that inhibited growth of cancer cells, for effects on JNK and tubulin and as a substrate for P-gp. Several pharmacological and biochemical assays were used to characterize signalling pathways of 2-phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole (PPTMB), a benzimidazole analogue, in prostate cancer cells. PPTMB inhibited proliferation of several human prostate cancer cell lines. It displayed similar activity against a P-gp-rich cell line, indicating that PPTMB was not a substrate for P-gp. PPTMB induced G2/M arrest of the cell cycle and subsequent apoptosis, using flow cytometry. Tubulin polymerization assays and Western blot analysis showed that PPTMB directly acted on tubulin and caused disruption of microtubule dynamics, inducing mitotic arrest and sustained high levels of cyclin B1 expression and Cdk1 activation. Subsequently, mitochondria-related apoptotic cascades were induced, including Bcl-2 and Bcl-xL phosphorylation, Mcl-1 down-regulation, truncated Bad formation and activ...Continue Reading

References

May 9, 1995·Proceedings of the National Academy of Sciences of the United States of America·S HaldarC M Croce
Jul 11, 1998·The Journal of Biological Chemistry·M F FavataJ M Trzaskos
Apr 5, 2001·Molecular and Cellular Biology·F CondorelliB Calabretta
Jan 16, 2002·Current Opinion in Genetics & Development·Claire R Weston, Roger J Davis
Jun 20, 2003·Cell Proliferation·Katrien VermeulenZwi N Berneman
Dec 10, 2003·Oncogene·Kapil N Bhalla
Oct 22, 2004·Journal of Biochemistry·Hiroshi NishinaToshiaki Katada
Dec 15, 2004·Biochemical and Biophysical Research Communications·Daisuke MizuchiOsamu Miura
Jun 14, 2005·Cancer Investigation·Federico Pellegrini, Daniel R Budman
Jul 13, 2005·The Journal of Cell Biology·Jun SunayamaYukiko Gotoh
Apr 19, 2006·The Journal of Cell Biology·Tatsiana TararukEleanor T Coffey
Jul 19, 2006·British Journal of Haematology·Paul CoppoAli G Turhan
Jun 1, 2007·Molecular Carcinogenesis·Ann M Bode, Zigang Dong
Nov 27, 2007·Biochemical Pharmacology·Joana MarinhoMaria São José Nascimento
Feb 14, 2008·Molecular Reproduction and Development·Shao-Chen SunQing-Yuan Sun
Mar 14, 2008·Current Molecular Medicine·Ozgur Kutuk, Anthony Letai
Jun 12, 2008·Biochimica Et Biophysica Acta·Renske van LeukenRob Wolthuis

❮ Previous
Next ❯

Citations

Oct 30, 2014·Chemical Biology & Drug Design·Rangappa S KeriBhari Mallanna Nagaraja
Nov 3, 2011·Journal of Signal Transduction·Gonzalo Rodríguez-BerrigueteMar Royuela

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis